News & Resources

Email Alerts

Email Address *
Mailing Lists *

Opexa Therapeutics CEO Invited to Join Personalized Medicine Panel at New York CEO Conference


THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, Opexa’s President and Chief Executive Officer, has been invited as a panel member to participate in the New York CEO Conference. The event will take place November 12 - 13, 2014, at the Apella in New York.

Mr. Warma will join other experts in the field of personalized medicine as they discuss the numerous advances that are being made in the industry and the implications for drug development, in the panel discussion, "How is Personalized Medicine Guiding Drug Development in 2014?"

The New York CEO Biotech Conference is a forum for industry Chief Executive Officers and decision makers in the life sciences. This invitation-only conference features luminaries in medicine and research, as well as executives of the next generation of leading biotechnology and pharmaceutical companies, who will explore the most relevant issues facing the industry today. Panel topics include outlooks on the 2015 healthcare industry, accelerating translation of research discoveries, financing trends and strategies, innovation in drug discovery, personalized medicine, innovative deal structures and more.

About Opexa

Opexa is a biopharmaceutical company developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on Opexa’s proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patient’s peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin. Opexa’s mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.

For more information visit the Opexa Therapeutics website at

Source: Opexa Therapeutics, Inc.

Opexa Therapeutics, Inc.

Karthik Radhakrishnan, 281-775-0600

Chief Financial Officer